Engineered immune cells take on deadly brain tumors
NCT ID NCT07180927
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a new treatment called 4sCAR-DLL3 CAR-T cells for people with DLL3-positive brain tumors, including glioblastoma and certain midline gliomas. The therapy uses a patient's own immune cells, modified to target and attack tumor cells. The trial will enroll 30 participants aged 2 to 70 whose tumors have come back or not responded to standard treatments. The main goals are to check safety and see if the cells shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 4sCAR-DLL3 CAR-T cells (a type of immune cell therapy)
- What this could lead to
- If successful, this could point toward a new treatment option for aggressive brain tumors like glioblastoma that have not responded to standard therapy.
- What could go wrong
- This is an early-phase trial with only 30 participants, so results may not apply to all patients. CAR-T therapy can cause serious side effects like cytokine release syndrome or neurotoxicity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE INTRINSIC PONTINE GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shenzhen Geno-immuno Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can trained immune cells outsmart brain tumors?
- Could a parasite drug fight childhood brain tumors?
- Could an antiparasitic drug boost radiation against childhood brain tumors?
- Engineered immune cells target deadly brain tumors in children
- Promising drug combo targets aggressive brain cancers in youth
- New hope for young brain cancer patients: targeted drug combo enters phase 2 trial